Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's a very strange company in terms of market cap - £130m by any stretch seems high for the amount of revenue they produce. However this doesn't seem to bother anyone, loads of volume the past couple of days with some hefty buys. I've held here since 2.5p (yes I sold some on the way up) but surely they've got to start making some serious cash soon to justify that valuation?
Nice steady rise again, healthy not to fast.
Big trade today 8.1m shares at 24.5p
welcome, a quiet board for quiet people :D
there was a 500,000 share sell if memory serves.
welcome to the board - it is quiet but insightful - which is tricky as this great company with a luminous future keeps its cards very close to its chest,
It's a bit of a quiet board. I can't see any specific reason for the drop other than placement but, it did go lower then I would have expected. The volume seems to have been better for a few days now I notice.
Just added this to my watchlist as tipped over on ONC. Why the sudden drop on no RNS?
TIA
Trek
Interesting article in Bloomberg today on Moderna, who revealed that the Covid vaccine was just the start, and they are building mRNA shots for HIV, cancer and the flu. ETX could be in pole position to assist
I checked the year end results 31/01/20 for Galapogas and they got £300K last year.
Revenue - In June 2020, we signed a collaboration agreement with Galapagos to identify new therapeutic approaches to modulate a specific mechanism involved in IPF and potentially in other fibrotic indications. Revenue during the year, of £0.3m, relates to the partial recognition of upfront payments and achieved milestones during the year, in accordance with IFRS 15.
Good to hear some news, don't give too much away do they. Could do with a few updates plenty going on.
Well if we can get any near their market cap I'll be a happy chap.
6% of shares on grant options - ouch
Are we Silence Therapeutics in disguise?
Could be us in months to come, look at the payments.....
https://www.londonstockexchange.com/news-article/SLN/40m-payment-from-astrazeneca-for-collaboration/14989763
Yes, I'm very surprised the price hasn't dropped towards the placing price, which is usually the case. It indicates strong latent demand here
Plenty of buys going through. It Has held up well with the placing obviously in demand, prime position at the right time.
“ However considering the length of time this company has been going they really need to start monetising their IP better rather than living off placings and scraps, so for me in the coming year they really do need to show that they have more than a sparkly toy.
Also, need to get some more institions involved because at least on Morningstar I don't see any funds involved other than Hargreave Hale.“
Must of read your post, pretty much answers it lol.
Well that was an unexpected placing...............particularly with what they said in the results. I'm not sure whether to partake or not
DD77 I understand your sentiment, but have become to realise with aim company’s what they say for forward looking predictions and potential earnings have to be careful. One eg BIDS...
I find the report as predicted for the previous 12 months but with a growing strength of investment, leadership and employees. Covid has exacerbated the need for quicker cures and medical breakthroughs for new and current medical solutions, to which ETX has years of development which is now starting to pay diligence.
The next 12 months in my opinion will be where we see all this come together , with a strong ceo and board who might not shout every £ earned or ‘ potential’ but will drive the business forward. Also they are heavily invested with their own money.
You are in a prime position with buying at 3p and taking profit with still holding a stake. I would happily hold here for at least 12months to see where this goes.
Outlook is exciting but with a degree of security for me.
Outlook
The last twelve months have been very encouraging as we have continued to develop our strategy and consistently demonstrated our scientific capabilities and further validation of our platforms. Importantly, with further investment to continue to develop our capabilities we now enter the next year ready to deliver on our exciting plans and with multiple opportunities.
The Company will look to maximise the value of its computational network driven biology platform through creating deal structures and positioning e-therapeutics as a global leader in network biology. Our ambition is to secure multiple research collaborations each year.
The Company will also look to commence RNAi platform partnerships/deals - an area currently commanding significant and attractive deals - and we anticipate business development opportunities in the second half of 2021.
Our priorities for the coming year are to:
• Expand computational platform collaborations
• Establish world-leading hepatocyte expertise
• Identify novel hepatocyte-expressed targets
• Commence RNAi in vivo studies and platform partnerships
The Company aims to maximise the value of its internal platform capabilities through two core channels - entering into platform collaborations with strategic partners and through the generation of in-house datasets to support development candidates. In addition to its partnerships, the Company intends to extract and retain further value from its platform by building an in-house pipeline of assets to provide out-licensing opportunities, through a data-driven and flexible partnering strategy at the right value inflection points.
Not sure if I was the only one, but I found the results very frustrating...........but then I tend to with this company. I've done very well, having originally invested at 3p, and further in the fund raise last year but I've sliced several times because I lack the conviction to hold. That is principally down to the lack of clarity on future revenue streams. No indication as to what the Galapagos milestone payments amounted to. I know Ali has previously advised that collaborations could be worth £100m but that is the only thing we have to hang our hat on.
Anyway, despite all this, the support the SP has (from somewhere - must be ii's because PI's can't deduct much from their comms!) is encouraging and will mean I remain a long term holder.
Interested in hearing others views............
Interesting - 10 x faster and 10 x cheaper.
Liver presents large commercial opportunities for RNA therapies
Focused delivery of siRNAs to the liver has striking advantages over small molecules in terms of timelines, costs and value inflection points: in contrast to the 3-4 years and c. US$3-5m to create a lead small molecule compound an siRNA attached to a GaINAc delivery system can be synthesised in 4-5 months and for a cost of c. US$200-300K. In addition, as one of the most sought-after drug modalities, there have been multiple collaboration transactions pre-IND filing as opposed to at a later stage (Phase 1-2) with small molec
https://www.etherapeutics.co.uk/wp-content/uploads/2021/05/Final-Results-January-2021.pdf
Well the sp seemed to of held well, no real off load of shares before news which is a positive sign. Will be good to hear what’s been going on behind the white coats.
See yall tomorrow.
I'm hoping for a substantial update and some good earnings going forward for the rest of this year. Possibly some more tie ups.
Fingers crossed.
All the main people seemed to have filled their boots in plenty of time,and at a decent high sp price.
Quite a few of my shares have taken a pounding today. Seems to be an aim down day.